CHEMICALSEXPORTSCAPEXCDMOAGROCHEMICALSCHINA+1

India Specialty Chemicals: ₹18,000 Cr in New Capex, But Only Two Companies Are Actually Converting It to ROCE

25 Apr 2026·9 min read·Free Report

30-second version

1.PI Industries delivered Q3 FY26 revenue of ₹1,847 Cr (+18% YoY) with EBITDA margins holding at 23.1%, while its CSM export order book crossed ₹8,000 Cr — the highest in company history, anchored by 5 new molecules entering commercial scale in FY26.
2.FIIs have turned net buyers in the BSE Chemicals index after 14 months of selling, adding ~₹2,200 Cr in Q1 CY26; DIIs remain overweight with heaviest positioning in PI Industries and Navin Fluorine, suggesting institutional conviction is narrowing to quality names rather than the broad sector.
3.The sector median 1-year forward PE sits at 38x against a 5-year average of 44x — a 14% discount — but the discount is deserved for capex-burdened names like Aarti Industries where ROCE has collapsed from 19% in FY22 to ~11% in FY25; the re-rating case is stock-specific, not sector-wide.

01What's happening

The India-US partial tariff rollback announced in April 2026 — cutting duties on ~85 specialty chemical categories from 10-15% to 5-7% — is the most material policy shift for export-oriented chemical companies since the PLI push of FY22. PI Industries and Navin Fluorine are the direct beneficiaries given their heavy US-facing CSM and fluorochemical pipelines. Separately, China's domestic chemical overcapacity problem is worsening: BASF and Bayer have both publicly flagged willingness to qualify second-source Indian suppliers for 6-8 agrochemical active ingredients, a process that takes 18-24 months but represents committed pipeline. Atomgrid's new Bengaluru R&D centre — opened this month — signals that the innovation side of China+1 is finally arriving in India, not just the toll-manufacturing piece. On the results front, Navin Fluorine's Q3 FY26 EBITDA grew 31% YoY to ₹118 Cr as its CDMO segment hit ₹96 Cr quarterly revenue for the first time, driven by a long-term contract with a top-5 global agrochemical MNC. Deepak Nitrite, however, reported a 9% YoY revenue decline in Q3 FY26 to ₹1,987 Cr as phenol and acetone spreads remained compressed, and the Dahej Phase 3 capex of ₹1,200 Cr is not expected to contribute meaningfully before Q2 FY27. SRF's fluorochemicals business continues to face pricing pressure in refrigerant gases as Chinese exports of HFCs remain aggressive despite putative capacity cuts.

02Why this matters for your portfolio

The structural argument for Indian specialty chemicals on a 2-3 year horizon is more durable now than it was in 2021-22, but for a completely different reason. In 2021, the thesis was China+1 manufacturing shift. In 2026, it is molecule-level qualification: global agrochemical and pharma companies are embedding Indian suppliers into their regulated supply chains, which creates switching costs that are genuinely sticky. PI Industries has 47 molecules in various stages of commercialisation across its CSM pipeline — each one, once qualified with a global innovator, generates 8-12 years of annuity-like revenue. That is not replicable quickly by a new entrant. Navin Fluorine's CDMO business is now operating at ~65% utilisation on its Surat multipurpose plant, with management guiding toward ₹500 Cr CDMO revenue in FY27 versus ₹340 Cr in FY26 — a 47% jump that, if delivered, will drive meaningful operating leverage given the fixed-cost-heavy nature of GMP manufacturing. From a return-on-capital perspective, PI Industries runs at ROCE of ~22% consistently, making it one of only three Indian chemical companies that can justify a 40x+ PE without being purely a growth-story bet. The India-EU trade deal framework, if finalised by end-CY26, adds another export corridor specifically for specialty and performance chemicals where EU's chemical registration requirements currently disadvantage non-EU suppliers. For a portfolio context, this sector gives you dollar-revenue exposure, a structural tailwind that does not depend on domestic consumption, and limited direct competition from listed Chinese peers — a combination that is hard to replicate in most other Indian sectors.

03Valuation check

Current multiples vs. 5-year averages. Verdict based on trailing twelve months earnings.

043 stocks worth watching

Fundamentally sound names with a clear thesis. Not buy/sell recommendations.

05Contrarian take

The bear case — what the bulls are missing

Here's what the bulls are missing: the China+1 narrative is being applied uniformly to a sector where the supply response is dangerously lopsided. Between FY23 and FY26, the top 10 listed Indian specialty chemical companies announced aggregate capex of over ₹18,000 Cr. Most of this — at Aarti Industries (₹4,000 Cr multi-year programme), Deepak Nitrite (₹2,800 Cr Dahej expansion), and Gujarat Fluorochemicals (₹3,500 Cr for EV fluoropolymers) — is chasing either commodity-adjacent markets or emerging technology bets that have no guaranteed demand. Aarti Industries is the most dangerous position right now: its net debt has ballooned to ~₹3,800 Cr as of December 2025, interest costs are consuming 18% of EBITDA, and the two large long-term contracts (estimated combined value ~₹12,000 Cr over 10 years) that management cited in FY22 as the demand anchor have seen one customer — a European specialty chemical major — quietly defer volumes by 12-18 months. ROCE at Aarti has compressed 800 bps over three years. The market is pricing Aarti at ~32x trailing earnings as if the capex cycle has already succeeded — it has not. Additionally, the fluorochemical space faces a specific regulatory risk: India's HFC phase-down schedule under Kigali Amendment commitments starts biting from FY28, affecting SRF's refrigerant gas revenue which still contributes ~28% of its chemicals segment. Bulls talking about SRF's EV battery fluoropolymer opportunity are pricing in a transition that is 3-4 years away while ignoring a near-term revenue hole.

06Sources

Primary sources only · No broker reports

Enjoyed this report?

Get a new one every Monday.

One flat plan — ₹199/month. Includes full archive, valuation tables, and watchlists.

Subscribe — ₹199/mo →